Swedish Company’s Shares Up 15% After Successful Pig Heart Transplantion To Human
Shares of little-known Swedish company Xvivo Perfusion AB have risen in price amid news of the world’s first successful pig heart transplantation to humans, Bloomberg writes.
At the peak of trading in Stockholm, the company’s securities rose to 291.5 Swedish kronor – 15.5% more expensive than at the close of previous trading, according to the site. The shares closed Tuesday’s trading up 6.14 per cent to SEK268. The company’s capitalisation rose to $926m.
Xvivo said its technology and equipment were used for an experimental operation that surgeons at the University of Maryland Medical Center performed on Jan. 7. During the eight-hour operation, they successfully transplanted the world’s first genetically modified pig heart into a 57-year-old man.
A team of surgeons in Europe is currently working on a similar project, Xvivo chief Doug Andersson said. The Swedish company’s method has previously been used in human-to-human organ transplants in clinical trials, and the technology has been awarded « breakthrough device » status by US regulators.
Xvivo has more than 20 years’ experience in transplant development and is headquartered in Gothenburg, Sweden.